Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody

Detalles Bibliográficos
Autores principales: Huang, Jiwei, Wang, Yueming, Zhang, Haoran, Hu, Xiaoyi, Wang, Ping, Cai, Wen, Yuan, Yichu, Zeng, Hao, Zhang, Jin, Kong, Wen, Huang, Yiran, Wang, Shuo, Guo, Jianming, Wei, Qiang, Xue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504141/
https://www.ncbi.nlm.nih.gov/pubmed/34363742
http://dx.doi.org/10.1002/cac2.12206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504141/
https://www.ncbi.nlm.nih.gov/pubmed/34363742
http://dx.doi.org/10.1002/cac2.12206

Ejemplares similares